AstraZeneca's cuts mean fresh talent for U.K. startups

In 2011, AstraZeneca ($AZN) jettisoned about 1,200 employees when it shuttered its R&D shop near Nottingham, U.K., but now the city is home to 22 life sciences startups launched by the drugmaker's former workers. Incubated by two universities and a local trade group, Nottingham's burgeoning biotech scene includes fast-growing CROs and consulting groups, mostly made up of ex-AZ researchers. Story

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.